Want to see IN:MANKIND full AI Analyst Report?
Mankind Pharma Ltd. (MANKIND) Ratios
Mankind Pharma Ltd. Ratios
IN:MANKIND's free cash flow for Q2 2027 was $0.00. For the 2027 fiscal year, IN:MANKIND's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.07 | 1.23 | 3.10 | 2.32 | 1.68 |
| Quick Ratio | 0.74 | 0.86 | 2.37 | 1.52 | 1.01 |
| Cash Ratio | 0.07 | 0.10 | 0.18 | 0.16 | 0.12 |
| Solvency Ratio | 0.24 | 0.20 | 0.97 | 0.78 | 0.57 |
| Operating Cash Flow Ratio | 0.39 | 0.43 | 1.02 | 0.96 | 0.35 |
| Short-Term Operating Cash Flow Coverage | 0.74 | 0.82 | 12.58 | 12.79 | 1.12 |
| Net Current Asset Value | $ -45.64B | $ -62.03B | $ 41.81B | $ 22.61B | $ 15.75B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.31 | 0.02 | 0.02 | 0.10 |
| Debt-to-Equity Ratio | 0.39 | 0.59 | 0.02 | 0.02 | 0.14 |
| Debt-to-Capital Ratio | 0.28 | 0.37 | 0.02 | 0.02 | 0.12 |
| Long-Term Debt-to-Capital Ratio | 0.15 | 0.28 | 0.00 | 0.00 | 0.01 |
| Financial Leverage Ratio | 1.72 | 1.94 | 1.28 | 1.31 | 1.49 |
| Debt Service Coverage Ratio | 0.85 | 0.91 | 11.82 | 9.18 | 1.94 |
| Interest Coverage Ratio | 4.27 | 6.17 | 146.90 | 38.53 | 92.00 |
| Debt to Market Cap | 0.08 | 0.09 | 0.00 | 0.00 | 0.02 |
| Interest Debt Per Share | 168.42 | 220.41 | 5.87 | 5.30 | 22.30 |
| Net Debt to EBITDA | 1.51 | 2.24 | -0.06 | -0.07 | 0.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 43.11% | 70.76% | 67.87% | 38.76% | 68.26% |
| EBIT Margin | 20.82% | 24.06% | 23.33% | 19.45% | 25.45% |
| EBITDA Margin | 27.02% | 29.15% | 27.18% | 23.18% | 27.59% |
| Operating Profit Margin | 19.13% | 20.61% | 39.54% | 18.51% | 23.92% |
| Pretax Profit Margin | 16.34% | 20.61% | 23.22% | 19.12% | 25.38% |
| Net Profit Margin | 13.40% | 16.31% | 18.51% | 14.66% | 18.42% |
| Continuous Operations Profit Margin | 13.57% | 16.44% | 18.79% | 14.98% | 18.67% |
| Net Income Per EBT | 82.01% | 79.12% | 79.73% | 76.70% | 72.60% |
| EBT Per EBIT | 85.41% | 100.02% | 58.71% | 103.29% | 106.09% |
| Return on Assets (ROA) | 6.81% | 7.17% | 15.99% | 13.19% | 15.67% |
| Return on Equity (ROE) | 11.74% | 13.89% | 20.43% | 17.24% | 23.29% |
| Return on Capital Employed (ROCE) | 12.66% | 11.39% | 41.52% | 20.61% | 28.53% |
| Return on Invested Capital (ROIC) | 9.08% | 8.00% | 33.01% | 15.86% | 18.65% |
| Return on Tangible Assets | 16.01% | 17.87% | 18.61% | 16.15% | 19.76% |
| Earnings Yield | 2.31% | 2.00% | 2.07% | 2.25% | 2.52% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.23 | 7.94 | 12.18 | 14.43 | 18.24 |
| Payables Turnover | 6.06 | 3.15 | 3.01 | 6.89 | 2.27 |
| Inventory Turnover | 3.79 | 1.70 | 2.14 | 3.57 | 1.40 |
| Fixed Asset Turnover | 3.95 | 3.75 | 3.29 | 2.84 | 3.26 |
| Asset Turnover | 0.51 | 0.44 | 0.86 | 0.90 | 0.85 |
| Working Capital Turnover Ratio | 16.12 | 4.23 | 2.99 | 4.12 | 3.59 |
| Cash Conversion Cycle | 80.42 | 144.20 | 79.47 | 74.47 | 119.51 |
| Days of Sales Outstanding | 44.32 | 46.00 | 29.96 | 25.29 | 20.02 |
| Days of Inventory Outstanding | 96.37 | 214.11 | 170.75 | 102.15 | 260.12 |
| Days of Payables Outstanding | 60.28 | 115.91 | 121.24 | 52.97 | 160.62 |
| Operating Cycle | 140.69 | 260.11 | 200.71 | 127.44 | 280.13 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 60.96 | 59.64 | 53.73 | 44.55 | 22.96 |
| Free Cash Flow Per Share | 45.79 | 48.25 | 44.19 | 23.78 | -35.59 |
| Dividend Paid and CapEx Coverage Ratio | 3.77 | 5.24 | 5.63 | 2.14 | 0.39 |
| Capital Expenditure Coverage Ratio | 4.02 | 5.24 | 5.63 | 2.14 | 0.39 |
| Operating Cash Flow Coverage Ratio | 0.40 | 0.28 | 10.39 | 10.47 | 1.05 |
| Operating Cash Flow to Sales Ratio | 0.18 | 0.20 | 0.21 | 0.20 | 0.12 |
| Free Cash Flow Yield | 2.28% | 1.96% | 1.91% | 1.67% | -2.50% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 43.28 | 49.99 | 48.41 | 44.45 | 39.75 |
| Price-to-Sales (P/S) Ratio | 5.80 | 8.15 | 8.96 | 6.52 | 7.32 |
| Price-to-Book (P/B) Ratio | 5.08 | 6.94 | 9.89 | 7.66 | 9.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 43.81 | 50.94 | 52.32 | 59.82 | -39.96 |
| Price-to-Operating Cash Flow Ratio | 32.91 | 41.22 | 43.03 | 31.93 | 61.95 |
| Price-to-Earnings Growth (PEG) Ratio | -7.55 | 16.81 | 0.98 | -4.21 | 3.00 |
| Enterprise Value Multiple | 22.97 | 30.19 | 32.90 | 28.05 | 26.80 |
| Enterprise Value | 886.11B | 1.07T | 924.37B | 568.41B | 575.46B |
| EV to EBITDA | 22.97 | 30.19 | 32.90 | 28.05 | 26.80 |
| EV to Sales | 6.21 | 8.80 | 8.94 | 6.50 | 7.40 |
| EV to Free Cash Flow | 46.89 | 55.02 | 52.22 | 59.67 | -40.36 |
| EV to Operating Cash Flow | 35.22 | 44.51 | 42.95 | 31.85 | 62.57 |
| Tangible Book Value Per Share | 10.35 | -50.61 | 197.03 | 146.54 | 110.38 |
| Shareholders’ Equity Per Share | 394.95 | 354.18 | 233.73 | 185.61 | 153.65 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.20 | 0.19 | 0.22 | 0.26 |
| Revenue Per Share | 345.95 | 301.67 | 257.99 | 218.25 | 194.25 |
| Net Income Per Share | 46.35 | 49.20 | 47.75 | 32.00 | 35.78 |
| Tax Burden | 0.82 | 0.79 | 0.80 | 0.77 | 0.73 |
| Interest Burden | 0.78 | 0.86 | 1.00 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.24 | 0.28 | 0.22 | 0.13 | 0.02 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.32 | 1.21 | 1.13 | 1.39 | 0.47 |
Currency in INR
